Medetomidine

10/01/2003 - "Bradycardia and bradypnoea were the consistent findings after medetomidine injection. "
02/01/1993 - "After medetomidine administration, marked bradycardia developed in all dogs and persisted for more than 2 hours. "
01/01/1989 - "Dogs receiving 40 micrograms/kg of medetomidine showed bradycardia, but higher blood pressures than dogs in the other groups. "
01/01/1989 - "From the cardiovascular changes induced with medetomidine, the profound bradycardia is most prominent. "
01/01/1989 - "Medetomidine also produced significant bradycardia, but the duration of this effect was not dose-dependent."

01/01/2008 - "Respiratory depression and bradycardia typically for medetomidine were seen in all three combinations, but quickly reversed after partial antagonisation. "
07/01/2010 - "Medetomidine induced significant respiratory depression with decrease in RR and TV in freely moving animals while cocaine increased TV, RR and minute ventilation (MV) with concomitant increase in heart rate when compared with time matched values from saline-treated animals. "
05/24/1997 - "The combination of medetomidine with fentanyl was unsuitable for obtaining surgical anaesthesia in spontaneously breathing animals owing to the severity of the respiratory depression at dosages needed for general anaesthesia."
01/01/1989 - "The slope of the CO2 response curve was significantly steeper after medetomidine (0.582 vs 0.269 1.min-1.mmHg), suggesting less respiratory depression when compared to the measurements under isoflurane. "
11/01/2003 - "Hypoventilation occurs with medetomidine sedation in dogs; however, respiratory depression becomes most significant when given in combination with other sedative or injectable agents. "

09/19/1997 - "Subcutaneous (s.c.) injection of medetomidine at 0.05, 0.1 and 0.3 mg/kg, 15 min before diazinon (75 mg/kg, orally) significantly and dose-dependently decreased the incidence of toxic manifestations, delayed the onset of tremors and death, and increased the 24 h survival rates to 70, 80 and 100%, respectively. "

01/01/2013 - "The mixture of 0.3 mg/kg body weight (b.w.) medetomidine (Med.), 4.0 mg/kg b.w. "
10/01/2012 - "The treatment groups were: CONTROL = saline bolus followed by saline CRI; MED1 = 2 μg/kg body weight (BW) medetomidine loading dose followed by 1 μg/kg BW per hour CRI; and MED2 = 4 μg/kg BW medetomidine loading dose followed by 2 μg/kg BW per hour CRI. "
01/01/2012 - "In ovo exposure of the chicks to medetomidine at 25 and 50 μg/egg did not significantly affect the body weight of the chicks as well as their morphometric measurements. "
12/01/2002 - "Medetomidine was injected by the intramuscular route at the rates of 3 and 5 microg/kg body weight into two groups of Indian elephants (Elephas maximus). "
11/01/2001 - "Baseline variables were recorded, and medetomidine (20 microg/kg of body weight, IM) was administered. "

07/01/2012 - "Our data suggest that medetomidine sedation can be used for simultaneous fMRI and electrophysiologic studies of normal and epileptic brain function, even though seizure duration after medetomidine administration was shorter than that in awake animals. "
07/01/2012 - "KA administration also triggered robust positive BOLD responses bilaterally in the hippocampus both in awake and medetomidine-sedated rats; however, in both animal groups some of the seizures detected in LFP recording did not cause detectable BOLD signal change. "
07/01/2012 - "Recurrent seizure activity induced by KA was detected in LFP both in medetomidine-sedated and awake rats, even though medetomidine sedation reduced the mean duration of individual seizures as compared to awake rats (33 ± 24 and 46 ± 34 s, respectively, mean ± SD p < 0.01). "
12/01/1994 - "Animals treated with L-medetomidine demonstrated more paroxysmal motor phenomena before clonic seizures than controls (P < 0.01) although the clonic seizure threshold was not altered. "
10/01/2010 - "In this study, functional magnetic resonance imaging of medetomidine-sedated rats was performed using novel rapid acquisition by sequential excitation and refocusing (RASER) fast imaging pulse sequence and simultaneous local field potential measurements during kainic acid-induced seizures. "